Cue Biopharma Sets 2026 Annual Meeting, Proposal Deadlines

Cue Biopharma ( (CUE) ) has issued an update.

Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026, and set February 28, 2026 as the key deadline for shareholders seeking to submit proposals for inclusion in the company’s proxy materials under SEC Rule 14a-8. The same February 28, 2026 cutoff applies to stockholder proposals and director nominations to be presented outside the proxy statement under the company’s bylaws, as well as to shareholders intending to solicit proxies for alternative board nominees under the SEC’s universal proxy rule, with missed deadlines allowing board-designated proxies to exercise discretionary voting on such matters.

The most recent analyst rating on (CUE) stock is a Hold with a $0.29 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.

Spark’s Take on CUE Stock

According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.

The score is primarily held down by weak financial performance (declining revenue and very large losses) and bearish technicals (below key moving averages with negative MACD). Corporate events modestly offset this by extending cash runway and adding partnership upside, while valuation remains unattractive/unclear due to negative earnings and no dividend.

To see Spark’s full report on CUE stock, click here.

More about Cue Biopharma

Cue Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development of targeted biologic therapies designed to modulate the immune system to treat cancer and other diseases. The company’s activities are centered on research, clinical development, and advancing immunotherapy platforms within the competitive biotech and oncology markets.

Average Trading Volume: 1,202,207

Technical Sentiment Signal: Sell

Current Market Cap: $27.97M

Learn more about CUE stock on TipRanks’ Stock Analysis page.